Robustaflavone, a potential non-nucleoside anti-hepatitis B agent

Antiviral Research

Volumn 39, Issue 2, 1998, Pages 81-88

  Zembower, David E ^a   Lin, Yuh Meei ^a   Flavin, Michael T ^a   Fa Ching Chen, ^b   Korba, Brent E ^c  

^a MediChem Research Inc   (United States)

^b TAMKANG UNIVERSITY   (Taiwan)

^c GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Biflavanoid; Combination therapy; Hepatitis B virus; Natural product; Non nucleoside antiviral agent

Indexed keywords

ANTIVIRUS AGENT; LAMIVUDINE; PENCICLOVIR; ROBUSTAFLAVONE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG TOXICITY; HEPATITIS B; HEPATITIS B VIRUS; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

ACYCLOVIR; ANTIVIRAL AGENTS; BIFLAVONOIDS; CELL LINE; DRUG SYNERGISM; FLAVONOIDS; HEPATITIS B VIRUS; LAMIVUDINE; MICROBIAL SENSITIVITY TESTS; VIRUS REPLICATION;

HEPATITIS B VIRUS; RHUS; TOXICODENDRON SUCCEDANEUM;

EID: 0032415023     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0166-3542(98)00033-3     Document Type: Article

References (27)

1. Aach R.D. The treatment of chronic type B viral hepatitis. Ann. Intern. Med. 109:1988;89-91.
2. Aye T.T., Bartholomeusz A., Shaw T., Breschkin A., Groenen L., Bowden S., McMillan J., Angus P., McCaughan G.W., Locarnini S. Hepatitis B virus polymerase mutations during famciclovir therapy in patients following liver transplantation. Hepatology. 24:1996;285A.
3. Aye T.T., Bartholomeusz A., Shaw T., Bowden S., Breschkin A., McMillan J., Angus P., Locarnini S. Hepatitis B virus polymerase mutations during antiviral therapy in a patient following liver transplantation. J. Hepatol. 26:1997;1148-1153.
4. Belen'kii M.S., Schinazi R.F. Multiple drug effect analysis with confidence interval. Antiviral Res. 25:1994;1-11.
5. Benhamou Y., Katlama C., Lunel F., Coutellier A., Dohin E., Hamm N., Tubiana R., Herson S., Poynard T., Opolon P. Effects of lamivudine on replication of hepatitis B virus in HIV-infected men. Ann. Intern. Med. 125:1996;705-712.
6. Chen F.-C., Lin Y.-M. Succedaneaflavanone - a new 6,6′′-binaringenin from Rhus succedanea. Phytochemistry. 14:1975;1644-1647.
7. Chen F.-C., Lin Y.-M. Rhusflavanone, a new biflavanone from the seeds of wax-tree. J. Chem. Soc. Perkin Trans. 1. 1976:1976;98-101.
8. Chen F.-C., Lin Y.-M., Liang C.-M. Biflavonyls from drupes of Rhus succedanea. Phytochemistry. 13:1974;276-278.
9. Chen F.-C., Lin Y.-M., Hung J.-C. Phenolic compounds from the heartwood of Garcinia multiflora. Phytochemistry. 14:1975;300-303.
10. Dusheiko G.M. The pathogenesis, diagnosis and management of viral hepatitis. Aliment. Pharmacol. Ther. 8:1994;229-253.
11. Hammer S.M., Katzenstein D.A., Hughes M.D., Gundacker H., Schooley R.T., Haubrich R.H., Henry W.K., Lederman M.M., Phair J.P., Niu M., Hirsch M.S., Merigan T.C. A trial comparing nucleoside monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimeter. New Engl. J. Med. 335:1996;1081-1090.
12. Hoofnagle J.H. Chronic hepatitis B. New Engl. J. Med. 323:1990;337-339.
13. Hoofnagle J.H., Lau D. New therapies for chronic hepatitis B. J. Viral Hepatitis. 4(Suppl. 1):1997;41-50.
14. Korba B.E. In vitro evaluation of combination therapies against hepatitis B virus replication. Antiviral Res. 29:1995;49-51.
15. Korba B.E., Boyd M.R. Penciclovir is a selective inhibitor of hepatitis B virus replication in cultured human hepatoblastoma cells. Antimicrob. Agents Chemother. 40:1996;1282-1284.
16. Korba B.E., Gerin J.L. Use of a standardized cell culture assay to assess activities of nucleoside analogs against hepatitis B virus replication. Antiviral Res. 19:1992;55-70.
17. Korba B.E., Milman G. A cell culture assay for compounds which inhibit hepatitis B virus replication. Antiviral Res. 15:1991;217-228.
18. Lin Y.-M., Chen F.-C. Robustaflavone from the seed-kernels of Rhus succedanea. Phytochemistry. 13:1974;1617-1619.
19. Lin Y.-M., Chen F.C. Agathisflavone from the drupes of Rhus succedanea. Phytochemistry. 13:1974;657-658.
20. Lin Y.-M., Anderson H., Flavin M.T., Pai Y.-H.S., Mata-Greenwood E., Pengsuparp T., Pezzuto J.M., Schinazi R.F., Hughes S.H., Chen F.-C. In vitro anti-HIV activity of biflavonoids isolated from Rhus succedanea and Garcinia multiflora. J. Nat. Prod. 60:1997;884-888.
21. Lin Y.-M., Zembower D.E., Flavin M.T., Schure R.M., Anderson H.M., Korba B.E., Chen F.-C. Robustaflavone, a naturally occurring biflavanoid, is a potent inhibitor of hepatitis B virus replication in vitro. Bioorg. Med. Chem. Lett. 7:1997;2325-2328.
22. Ling R., Mutimer D., Ahmed M., Boxall E.H., Elias E., Dusheiko G.M., Harrison T.J. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology. 24:1996;711-713.
23. Main J., Brown J.L., Karayiannis P., Georgiou P., Boyd M., Prince W., Thomas H. A double-blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. J. Hepatol. 21(Suppl. 1):1994;S32.
24. Martin, P., Friedman, L.S., 1992. Therapies for Hepatitis B virus: current status and future possibilities. In: Block, T.M., Junkind, D., Crowell, R.L., Denison, M., Walsh, L.R. (Eds), Innovations in Antiviral Development and the Detection of Virus Infections. Plenum Press, New York, pp. 111-120.
25. Maynard J.E., Kane M.A., Hadler S.C. Global control of hepatitis B through vaccination: role of hepatitis B vaccine in the expanded programme on immunization. Rev. Infect. Dis. 11:1989;S574-S578.
26. Regenstein F. New approaches to the treatment of chronic viral hepatitis B and C. Am. J. Med. 96(Suppl. 1A):1994;47S-51S.
27. Tipples G.A., Ma M.M., Fischer K.P., Bain V.G., Kneteman N.M., Tyrrell D.L.J. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology. 24:1996;714-717.